TEVA-MOXIFLOXACIN TABLET

देश: कनाडा

भाषा: अंग्रेज़ी

स्रोत: Health Canada

इसे खरीदें

सक्रिय संघटक:

MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE)

थमां उपलब्ध:

TEVA CANADA LIMITED

ए.टी.सी कोड:

J01MA14

INN (इंटरनेशनल नाम):

MOXIFLOXACIN

डोज़:

400MG

फार्मास्यूटिकल फॉर्म:

TABLET

रचना:

MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 400MG

प्रशासन का मार्ग:

ORAL

पैकेज में यूनिट:

30/100

प्रिस्क्रिप्शन प्रकार:

Prescription

चिकित्सीय क्षेत्र:

QUINOLONES

उत्पाद समीक्षा:

Active ingredient group (AIG) number: 0142242001; AHFS:

प्राधिकरण का दर्जा:

APPROVED

प्राधिकरण की तारीख:

2015-11-04

उत्पाद विशेषताएं

                                1
PRODUCT MONOGRAPH
PR
TEVA-MOXIFLOXACIN
Moxifloxacin tablets
400 mg moxifloxacin (as moxifloxacin hydrochloride)
Antibacterial Agent
Teva Canada Limited
Date of Revision:
30 Novopharm Court
Dec 02, 2020
Toronto, Ontario
M1B 2K9
Submission Control No: 241009
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
5
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
14
DRUG INTERACTIONS
.........................................................................................................
18
DOSAGE AND ADMINISTRATION
.....................................................................................
20
OVERDOSAGE
.......................................................................................................................
22
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 23
STORAGE AND STABILITY
.................................................................................................
29
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 29
PART II: SCIENTIFIC INFORMATION
...............................................................................
31
PHARMACEUTICAL INFORMATION
.................................................................................
31
CLINICAL TRIALS
.................................................................................................................
32
DETAILED PHA
                                
                                पूरा दस्तावेज़ पढ़ें
                                
                            

अन्य भाषाओं में दस्तावेज़

उत्पाद विशेषताएं उत्पाद विशेषताएं फ़्रेंच 02-12-2020

इस उत्पाद से संबंधित अलर्ट देखें

दस्तावेज़ इतिहास देखें